DOCSLIB.ORG

Expression Profiling of Cardiac Genes in Human Hypertrophic Cardiomyopathy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Expression Profiling of Cardiac Genes in Human Hypertrophic Cardiomyopathy View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Journal of the American College of Cardiology Vol. 38, No. 4, 2001 © 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01509-1 Hypertrophic Cardiomyopathy Expression Profiling of Cardiac Genes in Human Hypertrophic Cardiomyopathy: Insight Into the Pathogenesis of Phenotypes Do-Sun Lim, MD, Robert Roberts, MD, FACC, Ali J. Marian, MD, FACC Houston, Texas OBJECTIVES The goal of this study was to identify genes upregulated in the heart in human patients with hypertrophic cardiomyopathy (HCM). BACKGROUND Hypertrophic cardiomyopathy is a genetic disease caused by mutations in contractile sarcomeric proteins. The molecular basis of diverse clinical and pathologic phenotypes in HCM remains unknown. METHODS We performed polymerase chain reaction-select complementary DNA subtraction between normal hearts and hearts with HCM and screened subtracted libraries by Southern blotting. We sequenced the differentially expressed clones and performed Northern blotting to detect increased expression levels. RESULTS We screened 288 independent clones, and 76 clones had less than twofold increase in the signal intensity and were considered upregulated. Sequence analysis identified 36 genes including those encoding the markers of pressure overload-induced (“secondary”) cardiac hypertrophy, cytoskeletal proteins, protein synthesis, redox system, ion channels and those with unknown function. Northern blotting confirmed increased expression of skeletal muscle alpha-actin (ACTA1), myosin light chain 2a (MLC2a), GTP-binding protein Gs-alpha subunit (GNAS1), NADH ubiquinone oxidoreductase (NDUFB10), voltage-dependent anion channel 1 (VDAC1), four-and-a-half LIM domain protein 1 (FHL1) (also known as SLIM1), sarcosin (SARCOSIN) and heat shock 70kD protein 8 (HSPA8) by less than twofold. Expression levels of ACTA1, MLC2a and GNAS1 were increased in six additional and FHL1 in four additional hearts with HCM. CONCLUSIONS A diverse array of genes is upregulated in the heart in human patients with HCM, which could account for the diversity of clinical and pathologic phenotypes. Markers of secondary hypertrophy are also upregulated, suggesting commonality of pathways involved in HCM and the acquired forms of cardiac hypertrophy. Elucidation of the role of differentially expressed genes in HCM could provide for new therapeutic targets. (J Am Coll Cardiol 2001;38: 1175–80) © 2001 by the American College of Cardiology Hypertrophic cardiomyopathy (HCM) is a genetic disease transcription machinery leading to hypertrophy and other caused by mutations in the contractile sarcomeric proteins phenotypes of HCM. Thus, the pathogenesis of hypertro- (1). Hypertrophic cardiomyopathy is diagnosed clinically by phy, a common programmed response of the myocardium the presence of unexplained left ventricular hypertrophy and to any form of stress, whether caused by a genetic defect or pathologically by myocyte hypertrophy, disarray and inter- by an acquired condition, involves common pathways. stitial fibrosis (2). While the causality of mutant contractile Similarly, pathogenesis of diverse cardiac phenotypes also proteins in the pathogenesis of HCM is well established, results from upregulation of expression of a variety of genes the molecular bases of diverse cardiac phenotypes in HCM in response to the primary impetus provided by the mutant remain unknown. contractile protein (3). To identify genes that are upregu- We and others have proposed cardiac hypertrophy in lated in the heart in HCM, as the initial step for delineating HCM is a “compensatory” phenotype due to increased their role in induction of cardiac phenotypes, we performed ϩ cardiac myocyte stress or altered Ca 2 sensitivity of the subtraction hybridization between normal hearts and hearts contractile apparatus imparted by the mutant contractile with HCM followed by Northern blotting to confirm proteins (3). Accordingly, increased myocyte stress leads to upregulation of expression of the differentially expressed expression of a variety of cardiac genes that activate the genes in HCM. From the Section of Cardiology, Department of Medicine, Baylor College of METHODS Medicine, Houston, Texas. Supported by grants from the National Heart, Lung, and Blood Institute, Specialized Centers of Research (P50-HL42267-01) and an Estab- Subtraction hybridization and differential screening. lished Investigator Award (9640133N) from the AHA, National Center, Dallas, Each patient signed an informed consent, and the institu- Texas. Manuscript received January 31, 2001; revised manuscript received June 11, 2001, tional review board approved the protocols. Subtraction accepted June 26, 2001. hybridization was performed between two messenger ribo- 1176 Lim et al. JACC Vol. 38, No. 4, 2001 Gene Expression in HCM October 2001:1175–80 by subtracting the cDNA library generated from the heart Abbreviations and Acronyms with HCM from that of the normal heart. To reduce the ACTA1 ϭ skeletal muscle alpha-actin background, two rounds of suppression PCR were per- cDNA ϭ complementary deoxyribonucleic acid formed to amplify the differentially expressed genes. The ϭ FHL1 four-and-a-half LIM domain protein 1 enriched cDNA library was subcloned into a T/A cloning GNAS1 ϭ guanosine 5Ј-triphosphate (GTP)- binding protein Gs-alpha subunit plasmid vector, and the resulting products were transformed HCM ϭ hypertrophic cardiomyopathy into Escherichia coli and plated on agar plates. HSPA8 ϭ heat shock 70kD protein 8 To confirm that the subtracted clones represented differ- ϭ MLC2a myosin light chain 2A entially expressed genes and to reduce the number of false mRNA ϭ messenger ribonucleic acid NDUFB10 ϭ reduced nicotinamide adenine positives, colonies were initially screened by PCR-select dinucleotide ubiquinone oxidoreductase differential screening (CLONETECH). In brief, the cloned PCR ϭ polymerase chain reaction inserts were amplified by PCR using flanking primers, and SARCOSIN ϭ sarcosin 288 randomly selected clones in the forward-subtracted ϭ VDAC1 voltage-dependent anion channel 1 cDNA library were arrayed on three sets of 96-spot dot blot membranes in duplicates for subsequent hybridization. nucleic acid (mRNA) pools extracted from a heart with Probes were prepared by PCR amplification of the forward HCM and a normal heart, using a polymerase chain and reverse subtraction cDNA libraries, restriction enzyme reaction (PCR)-select complementary deoxyribonucleic acid digestion to remove the adapter sequences in order to reduce 32 (cDNA) subtraction kit (CLONETECH, Palo Alto, Cal- the background and radiolabeling with [ P] dCTP a 9 ␮ ifornia). In brief, left ventricular septal tissue was obtained specific activity of more than 10 cpm/ g. Each set of by myomectomy from a patient who had a long-standing membranes was hybridized either with forward or reverse history of symptomatic HCM with left ventricular outflow subtracted probe in ExpressHyb solution (CLONE- tract obstruction. A corresponding segment of the interven- TECH). After washing in high stringency conditions, the tricular septum was excised from an age- and gender- membranes were exposed to X-ray films in the presence of matched normal donor heart that was not used for cardiac intensifying screens for 24 h. transplantation. Tissues were frozen in liquid nitrogen and Sequencing. Differentially expressed clones were se- stored at Ϫ135°C until mRNA extraction. Total RNA and quenced using Big Dye Terminator Cycle Sequencing poly Aϩ RNA were extracted from hearts with HCM and Ready Reaction Kit on an ABI Genetic Analyzer 310 (PE control hearts side-by-side using the same reagents and Biosystem, Foster City, California). Sequences were ana- protocols and quantified by measuring absorption at lyzed using BLAST search of gene bank database. 260 nm. To select genes that were differentially expressed in Northern blotting. To confirm differential expression of the heart in HCM, 2 ␮g of polyAϩ mRNAs extracted were the putative candidate genes in HCM, Northern blotting used to generate subtraction cDNA libraries. The cDNA was performed on mRNA extracts from hearts with HCM library generated from the normal heart was subtracted from and control hearts. In brief, 10 ␮g aliquots of total RNA that of the heart with HCM (forward subtraction) through extracts were loaded onto a formaldehyde-agarose gel, two sets of hybridization, which resulted in a library subjected to electrophoresis and were transferred to a nylon enriched for genes that were upregulated in the heart with membrane (Bio-Rad Laboratories, Cambridge, Massachu- HCM. A reverse subtraction cDNA library was generated setts). The forward-subtracted cDNA probes were radiola- Figure 1. Subtracted clones dot blotted at 96-spot membranes. Membranes hybridized with radiolabeled forward and reverse subtracted complementary deoxyribonucleic acid libraries. Differentially expressed genes, identified by a twofold increase in signal intensity in the membrane hybridized with the forward subtraction probes, are shown by arrows. Clones hybridized with the reverse subtraction probes are considered background. JACC Vol. 38, No. 4, 2001 Lim et al. 1177 October 2001:1175–80 Gene Expression in HCM Table 1. Differentially Expressed Genes in the Heart in HCM Gene Symbol Accession # Locus # of Clone Sarcomeric Skeletal muscle ␣-actin ACTA1 J00068 1q42.13–q42.2 12 Myosin light chain 2a LOC58498
Load more

Recommended publications
  • Molecular Dissection of G-Protein Coupled Receptor Signaling and Oligomerization
    MOLECULAR DISSECTION OF G-PROTEIN COUPLED RECEPTOR SIGNALING AND OLIGOMERIZATION BY MICHAEL RIZZO A Dissertation Submitted to the Graduate Faculty of WAKE FOREST UNIVERSITY GRADUATE SCHOOL OF ARTS AND SCIENCES in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY Biology December, 2019 Winston-Salem, North Carolina Approved By: Erik C. Johnson, Ph.D. Advisor Wayne E. Pratt, Ph.D. Chair Pat C. Lord, Ph.D. Gloria K. Muday, Ph.D. Ke Zhang, Ph.D. ACKNOWLEDGEMENTS I would first like to thank my advisor, Dr. Erik Johnson, for his support, expertise, and leadership during my time in his lab. Without him, the work herein would not be possible. I would also like to thank the members of my committee, Dr. Gloria Muday, Dr. Ke Zhang, Dr. Wayne Pratt, and Dr. Pat Lord, for their guidance and advice that helped improve the quality of the research presented here. I would also like to thank members of the Johnson lab, both past and present, for being valuable colleagues and friends. I would especially like to thank Dr. Jason Braco, Dr. Jon Fisher, Dr. Jake Saunders, and Becky Perry, all of whom spent a great deal of time offering me advice, proofreading grants and manuscripts, and overall supporting me through the ups and downs of the research process. Finally, I would like to thank my family, both for instilling in me a passion for knowledge and education, and for their continued support. In particular, I would like to thank my wife Emerald – I am forever indebted to you for your support throughout this process, and I will never forget the sacrifices you made to help me get to where I am today.
    [Show full text]
  • Human CLPB) Is a Potent Mitochondrial Protein Disaggregase That Is Inactivated By
    bioRxiv preprint doi: https://doi.org/10.1101/2020.01.17.911016; this version posted January 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Skd3 (human CLPB) is a potent mitochondrial protein disaggregase that is inactivated by 3-methylglutaconic aciduria-linked mutations Ryan R. Cupo1,2 and James Shorter1,2* 1Department of Biochemistry and Biophysics, 2Pharmacology Graduate Group, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, U.S.A. *Correspondence: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.01.17.911016; this version posted January 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT Cells have evolved specialized protein disaggregases to reverse toxic protein aggregation and restore protein functionality. In nonmetazoan eukaryotes, the AAA+ disaggregase Hsp78 resolubilizes and reactivates proteins in mitochondria. Curiously, metazoa lack Hsp78. Hence, whether metazoan mitochondria reactivate aggregated proteins is unknown. Here, we establish that a mitochondrial AAA+ protein, Skd3 (human CLPB), couples ATP hydrolysis to protein disaggregation and reactivation. The Skd3 ankyrin-repeat domain combines with conserved AAA+ elements to enable stand-alone disaggregase activity. A mitochondrial inner-membrane protease, PARL, removes an autoinhibitory peptide from Skd3 to greatly enhance disaggregase activity. Indeed, PARL-activated Skd3 dissolves α-synuclein fibrils connected to Parkinson’s disease. Human cells lacking Skd3 exhibit reduced solubility of various mitochondrial proteins, including anti-apoptotic Hax1.
    [Show full text]
  • Skd3 (Human CLPB) Is a Potent Mitochondrial Protein Disaggregase That Is Inactivated By
    bioRxiv preprint first posted online Jan. 18, 2020; doi: http://dx.doi.org/10.1101/2020.01.17.911016. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Skd3 (human CLPB) is a potent mitochondrial protein disaggregase that is inactivated by 3-methylglutaconic aciduria-linked mutations Ryan R. Cupo1,2 and James Shorter1,2* 1Department of Biochemistry and Biophysics, 2Pharmacology Graduate Group, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, U.S.A. *Correspondence: [email protected] 1 bioRxiv preprint first posted online Jan. 18, 2020; doi: http://dx.doi.org/10.1101/2020.01.17.911016. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. ABSTRACT Cells have evolved specialized protein disaggregases to reverse toxic protein aggregation and restore protein functionality. In nonmetazoan eukaryotes, the AAA+ disaggregase Hsp78 resolubilizes and reactivates proteins in mitochondria. Curiously, metazoa lack Hsp78. Hence, whether metazoan mitochondria reactivate aggregated proteins is unknown. Here, we establish that a mitochondrial AAA+ protein, Skd3 (human CLPB), couples ATP hydrolysis to protein disaggregation and reactivation. The Skd3 ankyrin-repeat domain combines with conserved AAA+ elements to enable stand-alone disaggregase activity. A mitochondrial inner-membrane protease, PARL, removes an autoinhibitory peptide from Skd3 to greatly enhance disaggregase activity. Indeed, PARL-activated Skd3 dissolves α-synuclein fibrils connected to Parkinson’s disease.
    [Show full text]
  • AUSTRALIAN PATENT OFFICE (11) Application No. AU 199875933 B2
    (12) PATENT (11) Application No. AU 199875933 B2 (19) AUSTRALIAN PATENT OFFICE (10) Patent No. 742342 (54) Title Nucleic acid arrays (51)7 International Patent Classification(s) C12Q001/68 C07H 021/04 C07H 021/02 C12P 019/34 (21) Application No: 199875933 (22) Application Date: 1998.05.21 (87) WIPO No: WO98/53103 (30) Priority Data (31) Number (32) Date (33) Country 08/859998 1997.05.21 US 09/053375 1998.03.31 US (43) Publication Date : 1998.12.11 (43) Publication Journal Date : 1999.02.04 (44) Accepted Journal Date : 2001.12.20 (71) Applicant(s) Clontech Laboratories, Inc. (72) Inventor(s) Alex Chenchik; George Jokhadze; Robert Bibilashvilli (74) Agent/Attorney F.B. RICE and CO.,139 Rathdowne Street,CARLTON VIC 3053 (56) Related Art PROC NATL ACAD SCI USA 93,10614-9 ANCEL BIOCHEM 216,299-304 CRENE 156,207-13 OPI DAtE 11/12/98 APPLN. ID 75933/98 AOJP DATE 04/02/99 PCT NUMBER PCT/US98/10561 IIIIIIIUIIIIIIIIIIIIIIIIIIIII AU9875933 .PCT) (51) International Patent Classification 6 ; (11) International Publication Number: WO 98/53103 C12Q 1/68, C12P 19/34, C07H 2UO2, Al 21/04 (43) International Publication Date: 26 November 1998 (26.11.98) (21) International Application Number: PCT/US98/10561 (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, (22) International Filing Date: 21 May 1998 (21.05.98) GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, (30) Priority Data: TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO 08/859,998 21 May 1997 (21.05.97) US patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian 09/053,375 31 March 1998 (31.03.98) US patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, Fl, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, (71) Applicant (for all designated States except US): CLONTECH CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
    [Show full text]
  • THE FUNCTIONAL SIGNIFICANCE of MITOCHONDRIAL SUPERCOMPLEXES in C. ELEGANS by WICHIT SUTHAMMARAK Submitted in Partial Fulfillment
    THE FUNCTIONAL SIGNIFICANCE OF MITOCHONDRIAL SUPERCOMPLEXES in C. ELEGANS by WICHIT SUTHAMMARAK Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Dissertation Advisor: Drs. Margaret M. Sedensky & Philip G. Morgan Department of Genetics CASE WESTERN RESERVE UNIVERSITY January, 2011 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of _____________________________________________________ candidate for the ______________________degree *. (signed)_______________________________________________ (chair of the committee) ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ (date) _______________________ *We also certify that written approval has been obtained for any proprietary material contained therein. Dedicated to my family, my teachers and all of my beloved ones for their love and support ii ACKNOWLEDGEMENTS My advanced academic journey began 5 years ago on the opposite side of the world. I traveled to the United States from Thailand in search of a better understanding of science so that one day I can return to my homeland and apply the knowledge and experience I have gained to improve the lives of those affected by sickness and disease yet unanswered by science. Ultimately, I hoped to make the academic transition into the scholarly community by proving myself through scientific research and understanding so that I can make a meaningful contribution to both the scientific and medical communities. The following dissertation would not have been possible without the help, support, and guidance of a lot of people both near and far. I wish to thank all who have aided me in one way or another on this long yet rewarding journey. My sincerest thanks and appreciation goes to my advisors Philip Morgan and Margaret Sedensky.
    [Show full text]
  • The Specificity of Downstream Signaling for A1 and A2AR
    biomedicines Article The Specificity of Downstream Signaling for A1 and A2AR Does Not Depend on the C-Terminus, Despite the Importance of This Domain in Downstream Signaling Strength Abhinav R. Jain 1 , Claire McGraw 1 and Anne S. Robinson 1,2,* 1 Department of Chemical and Biomolecular Engineering, Tulane University, New Orleans, LA 70118, USA; [email protected] (A.R.J.); [email protected] (C.M.) 2 Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213, USA * Correspondence: [email protected]; Tel.: +1-412-268-7673 Received: 17 November 2020; Accepted: 9 December 2020; Published: 13 December 2020 Abstract: Recent efforts to determine the high-resolution crystal structures for the adenosine receptors (A1R and A2AR) have utilized modifications to the native receptors in order to facilitate receptor crystallization and structure determination. One common modification is a truncation of the unstructured C-terminus, which has been utilized for all the adenosine receptor crystal structures obtained to date. Ligand binding for this truncated receptor has been shown to be similar to full-length receptor for A2AR. However, the C-terminus has been identified as a location for protein-protein interactions that may be critical for the physiological function of these important drug targets. We show that variants with A2AR C-terminal truncations lacked cAMP-linked signaling compared to the full-length receptor constructs transfected into mammalian cells (HEK-293). In addition, we show that in a humanized yeast system, the absence of the full-length C-terminus affected downstream signaling using a yeast MAPK response-based fluorescence assay, though full-length receptors showed native-like G-protein coupling.
    [Show full text]
  • Identification of Novel GNAS Mutations in Intramuscular Myxoma Using Next- Generation Sequencing with Single-Molecule Tagged Molecular Inversion Probes Elise M
    Bekers et al. Diagnostic Pathology (2019) 14:15 https://doi.org/10.1186/s13000-019-0787-3 RESEARCH Open Access Identification of novel GNAS mutations in intramuscular myxoma using next- generation sequencing with single-molecule tagged molecular inversion probes Elise M. Bekers1,2* , Astrid Eijkelenboom1, Paul Rombout1, Peter van Zwam3, Suzanne Mol4, Emiel Ruijter5, Blanca Scheijen1 and Uta Flucke1 Abstract Background: Intramuscular myxoma (IM) is a hypocellular benign soft tissue neoplasm characterized by abundant myxoid stroma and occasional hypercellular areas. These tumors can, especially on biopsy material, be difficult to distinguish from low-grade fibromyxoid sarcoma or low-grade myxofibrosarcoma. GNAS mutations are frequently involved in IM, in contrast to these other malignant tumors. Therefore, sensitive molecular techniques for detection of GNAS aberrations in IM, which frequently yield low amounts of DNA due to poor cellularity, will be beneficial for differential diagnosis. Methods: In our study, a total of 34 IM samples from 33 patients were analyzed for the presence of GNAS mutations, of which 29 samples were analyzed using a gene-specific TaqMan genotyping assay for the detection of GNAS hotspot mutations c.601C > T and c602G > A in IM, and 32 samples using a novel next generation sequencing (NGS)-based approach employing single-molecule tagged molecular inversion probes (smMIP) to identify mutations in exon 8 and 9 of GNAS. Results between the two assays were compared for their ability to detect GNAS mutations with high confidence. Results: In total, 23 of 34 samples were successfully analyzed with both techniques showing GNAS mutations in 12 out of 23 (52%) samples.
    [Show full text]
  • Inactivation of Mitochondrial Complex I Stimulates Chloroplast Atpase in Physcomitrella (Physcomitrium Patens)
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.20.390153; this version posted November 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Inactivation of mitochondrial Complex I stimulates chloroplast ATPase in Physcomitrella (Physcomitrium patens). Marco Mellon a, Mattia Storti a, Antoni Mateu Vera Vives a, David M. Kramer b, Alessandro Alboresi a and Tomas Morosinotto a a. Department of Biology, University of Padova, 35121 Padova, Italy b. MSU-DOE Plant Research Laboratory, Michigan State University, East Lansing, MI 48824, United States of America; Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, United States of America. Corresponding author: Tomas Morosinotto, Dipartimento di Biologia, Università di Padova, Via Ugo Bassi 58B, 35121 Padova, Italy. Tel. +390498277484, Email: [email protected] Abstract While light is the ultimate source of energy for photosynthetic organisms, mitochondrial respiration is still fundamental for supporting metabolism demand during the night or in heterotrophic tissues. Respiration is also important for the metabolism of photosynthetically active cells, acting as a sink for excess reduced molecules and source of substrates for anabolic pathways. In this work, we isolated Physcomitrella (Physcomitrium patens) plants with altered respiration by inactivating Complex I of the mitochondrial electron transport chain by independent targeting of two essential subunits. Results show that the inactivation of Complex I causes a strong growth impairment even in fully autotrophic conditions in tissues where all cells are photosynthetically active.
    [Show full text]
  • Whole-Exome Sequencing Identifies Novel Somatic Mutations in Chinese Breast Cancer Patients
    HHS Public Access Author manuscript Author Manuscript Author ManuscriptJ Mol Genet Author Manuscript Med. Author Author Manuscript manuscript; available in PMC 2016 February 09. Published in final edited form as: J Mol Genet Med. 2015 December ; 9(4): . doi:10.4172/1747-0862.1000183. Whole-Exome Sequencing Identifies Novel Somatic Mutations in Chinese Breast Cancer Patients Yanfeng Zhang1, Qiuyin Cai1, Xiao-Ou Shu1, Yu-Tang Gao2, Chun Li3, Wei Zheng1, and Jirong Long1,* 1Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt- Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA 2Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China 3Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA Abstract Most breast cancer genomes harbor complex mutational landscapes. Somatic alterations have been predominantly discovered in breast cancer patients of European ancestry; however, little is known about somatic aberration in patients of other ethnic groups including Asians. In the present study, whole-exome sequencing (WES) was conducted in DNA extracted from tumor and matched adjacent normal tissue samples from eleven early onset breast cancer patients who were included in the Shanghai Breast Cancer Study. We discovered 159 somatic missense and ten nonsense mutations distributed among 167 genes. The most frequent 50 somatic mutations identified by WES were selected for validation using Sequenom MassARRAY system in the eleven breast cancer patients and an additional 433 tumor and 921 normal tissue/blood samples from the Shanghai Breast Cancer Study. Among these 50 mutations selected for validation, 32 were technically validated. Within the validated mutations, somatic mutations in the TRPM6, HYDIN, ENTHD1, and NDUFB10 genes were found in two or more tumor samples in the replication stage.
    [Show full text]
  • Electron Transport Chain Activity Is a Predictor and Target for Venetoclax Sensitivity in Multiple Myeloma
    ARTICLE https://doi.org/10.1038/s41467-020-15051-z OPEN Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma Richa Bajpai1,7, Aditi Sharma 1,7, Abhinav Achreja2,3, Claudia L. Edgar1, Changyong Wei1, Arusha A. Siddiqa1, Vikas A. Gupta1, Shannon M. Matulis1, Samuel K. McBrayer 4, Anjali Mittal3,5, Manali Rupji 6, Benjamin G. Barwick 1, Sagar Lonial1, Ajay K. Nooka 1, Lawrence H. Boise 1, Deepak Nagrath2,3,5 & ✉ Mala Shanmugam 1 1234567890():,; The BCL-2 antagonist venetoclax is highly effective in multiple myeloma (MM) patients exhibiting the 11;14 translocation, the mechanistic basis of which is unknown. In evaluating cellular energetics and metabolism of t(11;14) and non-t(11;14) MM, we determine that venetoclax-sensitive myeloma has reduced mitochondrial respiration. Consistent with this, low electron transport chain (ETC) Complex I and Complex II activities correlate with venetoclax sensitivity. Inhibition of Complex I, using IACS-010759, an orally bioavailable Complex I inhibitor in clinical trials, as well as succinate ubiquinone reductase (SQR) activity of Complex II, using thenoyltrifluoroacetone (TTFA) or introduction of SDHC R72C mutant, independently sensitize resistant MM to venetoclax. We demonstrate that ETC inhibition increases BCL-2 dependence and the ‘primed’ state via the ATF4-BIM/NOXA axis. Further, SQR activity correlates with venetoclax sensitivity in patient samples irrespective of t(11;14) status. Use of SQR activity in a functional-biomarker informed manner may better select for MM patients responsive to venetoclax therapy. 1 Department of Hematology and Medical Oncology, Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA, USA.
    [Show full text]
  • The Curious Case of Gαs Gain-Of-Function in Neoplasia Giulio Innamorati1* , Thomas M
    Innamorati et al. BMC Cancer (2018) 18:293 https://doi.org/10.1186/s12885-018-4133-z DEBATE Open Access The curious case of Gαs gain-of-function in neoplasia Giulio Innamorati1* , Thomas M. Wilkie2*, Havish S. Kantheti2, Maria Teresa Valenti3, Luca Dalle Carbonare3, Luca Giacomello1, Marco Parenti4, Davide Melisi5 and Claudio Bassi1 Abstract Background: Mutations activating the α subunit of heterotrimeric Gs protein are associated with a number of highly specific pathological molecular phenotypes. One of the best characterized is the McCune Albright syndrome. The disease presents with an increased incidence of neoplasias in specific tissues. Main body: A similar repertoire of neoplasms can develop whether mutations occur spontaneously in somatic tissues during fetal development or after birth. Glands are the most “permissive” tissues, recently found to include the entire gastrointestinal tract. High frequency of activating Gαs mutations is associated with precise diagnoses (e.g., IPMN, Pyloric gland adenoma, pituitary toxic adenoma). Typically, most neoplastic lesions, from thyroid to pancreas, remain well differentiated but may be a precursor to aggressive cancer. Conclusions: Here we propose the possibility that gain-of-function mutations of Gαs interfere with signals in the microenvironment of permissive tissues and lead to a transversal neoplastic phenotype. Keywords: GNAS, Heterotrimeric Gs protein, Activating mutation, Neoplasm, McCune Albright Syndrome, Intraductal papillary mucinous neoplasm, Fibrous dysplasia Background number of neoplasias, two hotspots on Gαs, Arg (R)201 Heterotrimeric Gαβγ proteins are central to sensing a and Gln (Q)227, are found mutated to three (Cys/His/ great number of extracellular stimuli. Each of the sub- Ser) or two (Arg/Leu) amino acids, respectively (Fig.
    [Show full text]
  • Genetic Diseases Related with Osteoporosis
    Chapter 2 Genetic Diseases Related with Osteoporosis Margarita Valdés-Flores, Leonora Casas-Avila and Valeria Ponce de León-Suárez Additional information is available at the end of the chapter http://dx.doi.org/10.5772/55546 1. Introduction Osteoporosis is a disease entity characterized by the progressive loss of bone mineral density (BMD) and the deterioration of bone microarchitecture, leading to the development of frac‐ tures. Its classification encompasses two large groups, primary and secondary osteoporosis [1]. Primary osteoporosis is the disease’s most common form and results from the progressive loss of bone mass related to aging and unassociated with other illness, a natural process in adult life; its etiology is considered multifactorial and polygenic. This form currently represents a growing worldwide health problem due in part, to the contemporary environmental condi‐ tions of modern civilization. Risk factors that are considered as “modifiable” also play an important role and include physical activity, dietary habits and eating disorders. Furthermore, there is another group of associated risk factors that are considered “non-modifiable”, including gender, age, race, a personal and/or family history of fractures that in turn, indirectly reflect the degree of genetic susceptibility to this disease [2-4]. Secondary osteoporosis encompasses a large heterogeneous group of primary conditions favoring osteoporosis development. Table 1 summarizes some of the disease entities associated to primary and secondary osteoporosis. 1.1. Genetic aspects of primary osteoporosis This form of osteoporosis results from the interaction of several environmental and genetic factors, leading to difficulties in its study. It is not easy to define the magnitude of the effect of genetic susceptibility since it is a trait determined by multiple genes whose products affect the bone phenotype; moreover, the environmental factors compromising bone mineral density are also difficult to analyze.
    [Show full text]